1. 1) Food and Drug Administration: Quantitative Assessment of the Prevalence of Unsuspected Uterine Sarcoma in Women Undergoing Treatment of Uterine Fibroids. Summary and Key Findings. April 17, 2014. https://www.fda.gov/media/88703/download (最終アクセス日2020年11月26日)
2. 2) Cholkeri-Singh A, Miller CE: Power morcellation in a specimen bag. J Minim Invasive Gynecol 2015; 22(2): 160. doi: 10.1016/j.jmig. 2014.10.012.
3. 3) Vargas MV, et al.: Open power morcellation versus contained power morcellation within an insufflated isolation bag: comparison of perioperative outcomes. J Minim Invasive Gynecol 2015
4. 22(3): 433-8. doi: 10.1016/j.jmig. 2014.11.010.
5. 4) Food and Drug Administration: FDA allows marketing of first-of-kind tissue containment system for use with certain laparoscopic power morcellators in select patients; Agency continues to warn against use of laparoscopic power morcellators for removal of uterus and uterine fibroids in the vast majority of women. April 7, 2016.
https://www.fda.gov/news-events/press-announcements/fda-allows-marketing-first-kind-tissue-containment-system-use-certain-laparoscopic-power (最終アクセス日2020年11月26日)